Daniel Ek’s body-scanning startup Neko Health just raised another $700M, according to TechCrunch. The new funding is being used to push forward a core idea the company already built its identity around: using proprietary body-scanning technology, paired with bloodwork, to assess a person's health.

That combination matters because it is not “just imaging.” Body-scanning without biological context can only show so much. By coupling scans with bloodwork, Neko Health is aiming to connect what a device can see with what biology is doing, so assessments are grounded in measurable signals rather than visuals alone. That framing is the center of the business thesis behind this $700M raise: scale a health assessment workflow that is fast enough to be continuous, while still anchored to lab-grade evidence through bloodwork.

If you zoom out, this is the kind of capital move that typically happens when investors believe the market will pay for repeatable measurement, not one-off diagnostics. Health assessment is sticky when it becomes part of a routine, not a rare event. And routine measurement changes the economics of healthcare delivery and insurance-like funding models because the unit of value shifts from “treat an episode” to “monitor risk signals.” Body-scanning plus bloodwork is designed to sit in that middle ground, where technology helps interpret the human state more often than classic clinician workflows can.

For decision-makers, the interesting part is how this funding intersects with the regulatory reality of health tech. Even if a company has excellent models and hardware, the path to broad use usually depends on demonstrating clinical validity for what the system claims to assess. The scan-and-bloodwork pairing is potentially a regulatory sweet spot because it can be evaluated against known biological outcomes. In plain terms: the company is not only collecting images, it is also connecting those images to blood-based data that regulators and clinicians already understand how to treat as evidence.

There is also a product and operations incentive hidden in the $700M number. Bloodwork is not free, and it is not trivial logistics. Adding capital often signals that the company is working on making the overall experience work end-to-end, including how scanning fits into a broader health journey that can include lab work. That means Neko Health likely needs to nail throughput, compliance, data handling, and partner operations with the same seriousness it brings to scanning hardware accuracy.

Second-order effects show up at the board level, too. A “raises another $700M” moment is rarely just about runway. It usually changes bargaining power with partners, strengthens the team’s ability to recruit technical and clinical talent, and accelerates time-to-results for validation studies. In a field where credibility is everything, additional capital can also help convert early proof into the kind of dataset and clinical evidence that makes adoption discussions easier with healthcare stakeholders who want to reduce uncertainty.

Finally, this is a signal to peers building at the intersection of consumer-meets-clinical and devices-meets-labs. Neko Health’s approach is explicitly a hybrid: proprietary scanning plus bloodwork. That is a clear statement of what investors and operators may now view as the winning architecture for digital health assessment. If it works, it could pressure competitors that rely on vision alone, push incumbents to revisit measurement strategies, and raise the bar for anyone trying to quantify health without pairing technological outputs to biological references.

For executives, the strategic stakes are straightforward. If you are investing in or building health measurement tech, the question is no longer “can we measure humans with a sensor?” It is “can we measure humans with enough biological grounding that people, partners, and regulators take the assessment seriously?” Neko Health’s $700M raise suggests the market wants that answer sooner, and it wants the scan-and-bloodwork loop to become a scalable product, not a pilot.